PhRMA plans expanded post-election ad blitz

Pharma's lobbying group is expanding its marketing for 2017, gearing up for a big post-election fight.

As a spokeswoman for Pharmaceutical Research and Manufacturers of America (PhRMA) told FiercePharmaMarketing, the organization will mount a bigger marketing effort for 2017 to push the group's message to a wider audience. And PhRMA will spend a "massive" amount of money on that effort, according to Politico, although the spokeswoman declined to confirm that to FiercePharmaMarketing.

Roll Call recently reported that PhRMA has already spent a near-record $11.7 million in lobbying this year.


Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

The 2017 campaign will remain centered around PhRMA’s “Hope to Cures” campaign that launched in 2014 highlighting patient and pharma scientists. Until now, the campaign until now has run mostly in Washington, DC, along with just a few select states.

"Patients like 5-year-old Rhys, who lives with Type 1 diabetes, and Jamie, who has a rare blood cancer, are a few of the stories featured in the (2016) campaign. Next year's campaign will just be amplifying our messages to a broader audience,” she said.

The increased spend is part of a larger overhaul at the lobbying group. PhRMA is facing the departure of its top Republican and Democratic representatives, but it's already recruited new hires to help with the anticipated political battle over drug prices. Both U.S. presidential candidates have slammed rising drug costs and have promised to pursue the issue if elected, and dubious drug manufacturer practices of pulling major price hikes on older drugs--seen in action by the likes of Turing and Valeant Pharmaceuticals ($VRX)--have further dinged Big Pharma's reputation.

Meanwhile, though, individual drugmakers have already been pitching in with their own ads to help with reputation repair. Efforts like Pfizer’s ($PFE) current “Before it Became a Medicine” campaign, for instance, show the drug development process from the perspective of the researchers.

- read the Politico article
- get more from Roll Call

Related Articles:
PhRMA hopes to polish pharma's tarnished rep with patient-focused ad campaign
Teva wins controversial PhRMA bid despite protests from branded rivals
Tired of playing 'scapegoat' in a tough election year, BIO gears up for a fight
What's pharma got to say about pricing? PhRMA has some ideas


Suggested Articles

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.